Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: Implication for residual immune activation from the results of a clinical trial

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  D'Ettorre, Gabriella ^a   Baroncelli, Silvia ^b   Micci, Luca ^c   Ceccarelli, Giancarlo ^a   Andreotti, Mauro ^b   Sharma, Prachi ^c   Fanello, Gianfranco ^d   Fiocca, Fausto ^d   Cavallari, Eugenio Nelson ^a   Giustini, Noemi ^a   Mallano, Alessandra ^b   Galluzzo, Clementina M ^b   Vella, Stefano ^b   Mastroianni, Claudio M ^d   Silvestri, Guido ^c,e   Paiardini, Mirko ^c,e   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c EMORY UNIVERSITY   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; DARUNAVIR PLUS RITONAVIR; DNA 16S; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LIPOPOLYSACCHARIDE; LOPINAVIR PLUS RITONAVIR; GAMMA INTERFERON; INTERLEUKIN 17;

ADULT; ARTICLE; BLOOD CELL; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE BIOPSY; INTESTINE CELL; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PILOT STUDY; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TREATMENT DURATION; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; INTESTINE; LYMPHOCYTE ACTIVATION; PATHOLOGY; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-17; INTESTINES; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; TH17 CELLS; VIRAL LOAD;

EID: 84908406134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109791     Document Type: Article

References (60)

1. Bhaskaran K, Hamouda O, Sannes M., Boufassa F, Johnson AM, et al. (2008) CASCADE Collaboration. Changes in the risk of death after HIV seroconver-sion compared with mortality in the general population. JAMA 300:51-59.
2. Antiretroviral Therapy Cohort Collaboration. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 372: 293-299.
3. Deeks SG, Phillips AN. (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 338:a3172.
4. Kuller LH, Tracy R, Belloso W., De Wit S, Drummond F, et al. (2008) INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5:e203.
5. Piconi S, Trabattoni D, Gori A., Parisotto S, Magni C, et al. (2010) Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS 24:1991-2000.
6. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD (2012) Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012:670957.
7. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G (2012) HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol 2012:515962.
8. Cassol E, Malfeld S, Mahasha P., Bond R, Slavik T, et al. (2013) Impaired CD4+ T-Cell Restoration in the Small Versus Large Intestine of HIV-1-Positive South Africans Receiving Combination Antiretroviral Therapy. J Infect Dis 208:1113-1122.
9. Jain V, Hartogensis W, Bacchetti P., Hunt PW, Hatano H, et al. (2013) Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. J Infect Dis 208:1202-1211.
10. Brenchley JM, Price DA, Schacker T.W., Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12:1365-1371.
11. Marchetti G, Tincati C, Silvestri G (2013) Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 26:2-18.
12. Chege D, Sheth PM, Kain T, Kim C.J., Kovacs C., et al. (2011) Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25:741-749.
13. Mavigner M, Cazabat M, Dubois M., L'Faqihi FE, Requena M, et al. (2012) Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest 122:62-69.
14. Guglani L, Khader SA (2010) Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS 5:120-127.
15. Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 19:281-286.
16. Hartigan-O'Connor DJ, Hirao LA, McCune JM, Dandekar S (2011) Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS 6:221-227.
17. Hunt PW (2010) Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS 5:189-193.
18. Paiardini M (2010) Th17 cells in natural SIV hosts. Curr Opin HIV AIDS 5:166-172.
19. Ancuta P, Monteiro P, Sekaly RP (2010) Th17 lineage commitment and HIV-1 pathogenesis. Curr Opin HIV AIDS 5:158-165.
20. Kanwar B, Favre D, McCune JM (2010) Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 5:151-157.
21. Noma T (2010) [Helper T cell paradigm: Th17 and regulatory T cells involved in autoimmune inflammatory disorders, pathogen defense and allergic diseases]. Nihon Rinsho Meneki Gakkai Kaishi 33:262-271.
22. Tesmer LA, Lundy SK, Sarkar S, Fox DA (2008) Th17 cells in human disease. Immunol Rev 223:87-113.
23. Pelletier M, Maggi L, Micheletti A., Lazzeri E, Tamassia N, et al. (2010) Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115:335-343.
24. Dandekar S, George MD, Bäumler AJ (2010) Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS 5:173-178.
25. Brenchley JM, Paiardini M, Knox K.S., Asher AI, Cervasi B, et al. (2008) Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112:2826-2835.
26. Gordon SN, Cervasi B, Odorizzi P., Silverman R, Aberra F, et al. (2010) Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol 185:5169-5179.
27. El Hed A, Khaitan A, Kozhaya L., Manel N, Daskalakis D, et al. (2010) Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 201:843-854.
28. Ciccone EJ, Greenwald JH, Lee P.I., Biancotto A., Read SW, et al. (2011) CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-Term nonprogressors. J Virol 85:5880-5888.
29. Salgado M, Rallón NI, Rodés B, López M, Soriano V., et al. (2011) Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. Clin Immunol 139:110-114.
30. Raffatellu M, Santos RL, Verhoeven D.E., George MD, Wilson RP, et al. (2008) Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 14:421-428.
31. Favre D, Lederer S, Kanwar B., Ma ZM, Proll S, et al. (2009) Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 5:e1000295.
32. Cecchinato V, Trindade CJ, Laurence A, Heraud J.M., Brenchley JM, et al. (2008) Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 1:279-288.
33. Estes JD, Harris LD, Klatt N.R., Tabb B., Pittaluga S, et al. (2010) Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 6:e1001052.
34. Chahroudi A, Bosinger SE, Vanderford T.H., Paiardini M., Silvestri G (2012) Natural SIV hosts: showing AIDS the door. Science 335:1188-1193.
35. Micci L, Cervasi B, Ende Z.S., Iriele RI, Reyes-Aviles E, et al. (2012) Paucity of IL-21-producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood 120:3925-3935.
36. Lambotte O, Delfraissy JF (2006) [HIV controllers: a homogeneous group of HIV-1 infected patients with a spontaneous control of viral replication]. Pathol Biol (Paris) 54:566-571.
37. Westrop SJ, Qazi NA, Pido-Lopez J, Nelson M.R., Gazzard B., et al. (2009) Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers. PLoS One 4:e5474.
38. Brandt L, Benfield T, Mens H., Clausen LN, Katzenstein TL, et al. (2011) Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr 57:101-108.
39. Hartigan-O'Connor DJ, Abel K, Van Rompay KK, Kanwar B, McCune JM (2012) SIV replication in the infected rhesus macaque is limited by the size of the preexisting TH17 cell compartment. Sci Transl Med 4:136ra69.
40. Costiniuk CT, Angel JB (2012) Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol 5:596-604.
41. Hayes TL, Asmuth DM, Critchfield J.W., Knight TH, McLaughlin BE, et al. (2013) Impact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa. AIDS 27:867-877.
42. Ciccone EJ, Read SW, Mannon P.J., Yao MD, Hodge JN, et al. (2010) Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol 3:172-181.
43. Prendergast A, Prado JG, Kang Y.H., Chen F., Riddell LA, et al. (2010) HIV-1 infection is characterized by profound depletion of CD161+Th17 cells and gradual decline in regulatory T cells. AIDS 24:491-502.
44. Macal M, Sankaran S, Chun T.W., Reay E., Flamm J, et al. (2008) Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 1:475-488.
45. Guadalupe M, Reay E, Sankaran S., Prindiville T, Flamm J, et al. (2003) Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77:11708-11717.
46. George MD, Reay E, Sankaran S., Dandekar S (2005) Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79:2709-2719.
47. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, et al. (2006) Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 3:e484.
48. Tincati C, Biasin M, Bandera A., Violin M, Marchetti G, et al. (2009) Early initiation of highly active antiretroviral therapy fails to reverse immunovir-ological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther 14:321-330.
49. Sheth PM, Chege D, Shin L.Y., Huibner S., Yue FY, et al. (2008) Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol 1:382-388.
50. Lok JJ, Degruttola V (2012) Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients. Biometrics 68:745-754.
51. Guadalupe M, Sankaran S, George M.D., Reay E., Verhoeven D, et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80:8236-8247.
52. Yukl SA, Gianella S, Sinclair E., Epling L, Li Q, et al. (2010) Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202:1553-1561.
53. Brenchley JM, Price DA, Douek DC (2006) HIV disease: fallout from a mucosal catastrophe? Nat Immunol 7:235-239.
54. d'Ettorre G., Paiardini M, Zaffiri L., Andreotti M, Ceccarelli G, et al. (2011) HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res; 9:148-153.
55. d'Ettorre G., Paiardini M, Ceccarelli G., Silvestri G, Vullo V (2011) HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses 27:355-364.
56. Papasavvas E, Pistilli M, Reynolds G., Bucki R, Azzoni L, et al. (2009) Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 23:369-375.
57. Jiang W, Lederman MM, Hunt P, Sieg S.F., Haley K., et al. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 199:1177-1185.
58. Wallet MA, Rodriguez CA, Yin L, Saporta S., Chinratanapisit S, et al. (2010) Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 24:1281-1290.
59. Merlini E, Bai F, Bellistrì GM, Tincati C, d'Arminio Monforte A, et al. (2011) Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 6:e18580.
60. Baroncelli S, Galluzzo CM, Pirillo M.F., Mancini MG, Weimer LE, et al.(2009) Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with, 50copies/ml HIV-1 RNA. J Clin Virol 46:367-370.